Aclaris Therapeutics Inc logo

ACRS - Aclaris Therapeutics Inc Share Price

$18.22 0.2  1.0%

Last Trade - 22/01/21

Sector
Healthcare
Size
Mid Cap
Market Cap £571.5m
Enterprise Value £540.6m
Revenue £4.38m
Position in Universe 2931st / 6630
Bullish
Bearish
Unlock ACRS Revenue
Momentum
Relative Strength (%)
1m +131%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -25.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 1.68 6.15 4.23 6.29 6.16
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, AclarisTherapeutics Inc revenues increased 57% to $4.9M. Net lossbefore extraordinary items decreased 60% to $37.6M.Revenues reflect Therapeutics segment increase from $0K to$529K. Lower net loss reflects Research and Development -gross decrease of 58% to $20.6M (expense), Goodwillimpairment decrease from $18.5M (expense) to $0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ACRS Revenue Unlock ACRS Revenue

Net Income

ACRS Net Income Unlock ACRS Revenue

Normalised EPS

ACRS Normalised EPS Unlock ACRS Revenue

PE Ratio Range

ACRS PE Ratio Range Unlock ACRS Revenue

Dividend Yield Range

ACRS Dividend Yield Range Unlock ACRS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ACRS EPS Forecasts Unlock ACRS Revenue
Profile Summary

Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a physician-led, biopharmaceutical company focused on immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. Its drug candidates are ATI-450, ATI-1777, ATI-2138, JAK1/JAK3 Inhibitor, A-101, ATI-501 and ATI-502. Its ATI-450, an investigational oral. small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK inhibitor compound, for the treatment of atopic dermatitis. The Company is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases. Its indirect, wholly owned subsidiary is Confluence Discovery Technologies, Inc.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated July 13, 2012
Public Since October 7, 2015
No. of Shareholders: 60
No. of Employees: 77
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 42,919,291
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ACRS Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ACRS
Upcoming Events for ACRS
Frequently Asked Questions for Aclaris Therapeutics Inc
What is the Aclaris Therapeutics Inc share price?

As of 22/01/21, shares in Aclaris Therapeutics Inc are trading at $18.22, giving the company a market capitalisation of £571.5m. This share price information is delayed by 15 minutes.

How has the Aclaris Therapeutics Inc share price performed this year?

Shares in Aclaris Therapeutics Inc are currently trading at $18.22 and the price has moved by 1.04k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aclaris Therapeutics Inc price has moved by 0.874k% over the past year.

What are the analyst and broker recommendations for Aclaris Therapeutics Inc?

Of the analysts with advisory recommendations for Aclaris Therapeutics Inc, there are there are currently 3 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Aclaris Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Aclaris Therapeutics Inc next release its financial results?

Aclaris Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Aclaris Therapeutics Inc dividend yield?

Aclaris Therapeutics Inc does not currently pay a dividend.

Does Aclaris Therapeutics Inc pay a dividend?

Aclaris Therapeutics Inc does not currently pay a dividend.

When does Aclaris Therapeutics Inc next pay dividends?

Aclaris Therapeutics Inc does not currently pay a dividend.

How do I buy Aclaris Therapeutics Inc shares?

To buy shares in Aclaris Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Aclaris Therapeutics Inc?

Shares in Aclaris Therapeutics Inc are currently trading at $18.22, giving the company a market capitalisation of £571.5m.

Where are Aclaris Therapeutics Inc shares listed? Where are Aclaris Therapeutics Inc shares listed?

Here are the trading details for Aclaris Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ACRS
What kind of share is Aclaris Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Aclaris Therapeutics Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Aclaris Therapeutics Inc share price forecast 2021?

Shares in Aclaris Therapeutics Inc are currently priced at $18.22. At that level they are trading at 9.77% discount to the analyst consensus target price of 0.00.

Analysts covering Aclaris Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.16 for the next financial year.

How can I tell whether the Aclaris Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aclaris Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 0.612k%. At the current price of $18.22, shares in Aclaris Therapeutics Inc are trading at 0.481k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Aclaris Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Aclaris Therapeutics Inc.

Who are the key directors of Aclaris Therapeutics Inc?

Aclaris Therapeutics Inc's management team is headed by:

Frank Ruffo - CFD
Neal Walker - PRE
Kamil Ali-Jackson - CFD
Anand Mehra - IND
Christopher Molineaux - IND
William Humphries - IND
David Gordon - OTH
Maxine Gowen - IND
Vincent Milano - DRC
Who are the major shareholders of Aclaris Therapeutics Inc?

Here are the top five shareholders of Aclaris Therapeutics Inc based on the size of their shareholding:

Renaissance Technologies LLC Hedge Fund
Percentage owned: 7.09% (3.43m shares)
Adage Capital Management, L.P. Hedge Fund
Percentage owned: 5.17% (2.50m shares)
Rock Springs Capital Management LP Hedge Fund
Percentage owned: 4.57% (2.21m shares)
Samsara BioCapital, LLC Venture Capital
Percentage owned: 4.45% (2.15m shares)
Moshe (Arkin) Individual Investor
Percentage owned: 4.06% (1.97m shares)
Similar to ACRS
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.